Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 1,154 Shares

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,154 shares of the firm’s stock in a transaction that occurred on Tuesday, January 11th. The stock was sold at an average price of $25.11, for a total transaction of $28,976.94. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

NASDAQ:INSM opened at $23.73 on Friday. The firm has a fifty day simple moving average of $28.05 and a 200 day simple moving average of $27.35. Insmed Incorporated has a 1-year low of $22.00 and a 1-year high of $45.44. The stock has a market capitalization of $2.81 billion, a PE ratio of -6.05 and a beta of 2.17. The company has a current ratio of 8.52, a quick ratio of 7.92 and a debt-to-equity ratio of 1.13.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.13). Insmed had a negative net margin of 243.96% and a negative return on equity of 108.34%. The business had revenue of $46.80 million for the quarter, compared to analyst estimates of $49.23 million. During the same period in the prior year, the business earned ($0.63) EPS. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. On average, equities analysts predict that Insmed Incorporated will post -3.77 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in INSM. Price T Rowe Associates Inc. MD lifted its holdings in shares of Insmed by 27.2% during the second quarter. Price T Rowe Associates Inc. MD now owns 14,372,685 shares of the biopharmaceutical company’s stock worth $409,047,000 after buying an additional 3,070,140 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Insmed by 438.4% during the third quarter. Nisa Investment Advisors LLC now owns 5,895 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 4,800 shares in the last quarter. Altium Capital Management LP lifted its holdings in shares of Insmed by 84.4% during the second quarter. Altium Capital Management LP now owns 203,354 shares of the biopharmaceutical company’s stock worth $5,787,000 after buying an additional 93,100 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Insmed by 5.7% during the second quarter. UBS Asset Management Americas Inc. now owns 123,000 shares of the biopharmaceutical company’s stock worth $3,501,000 after buying an additional 6,596 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in shares of Insmed during the third quarter worth $9,464,000.

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Insmed in a research note on Monday, December 6th. They set an “overweight” rating and a $45.00 price target for the company. Zacks Investment Research cut shares of Insmed from a “hold” rating to a “sell” rating in a research note on Thursday, December 30th. HC Wainwright reissued a “buy” rating and issued a $52.00 target price on shares of Insmed in a research note on Friday, October 8th. Finally, Cantor Fitzgerald began coverage on shares of Insmed in a research note on Friday, October 8th. They issued an “overweight” rating and a $60.00 target price for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $50.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Story: What can cause a stock to outperform?

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.